Lipax (proliposomal intravesical paclitaxel) / TesoRx 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Lipax (proliposomal intravesical paclitaxel) / TesoRx
    Journal:  AAV gene therapy for Tay-Sachs disease. (Pubmed Central) -  Apr 27, 2022   
    Patient TSD-001 was treated at 30 months with an equimolar mix of AAVrh8-HEXA and AAVrh8-HEXB administered intrathecally (i.t.), with 75% of the total dose (1 × 10 vector genomes (vg)) in the cisterna magna and 25% at the thoracolumbar junction...TSD-002 developed anticonvulsant-responsive seizures at 2 years of age. This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.
  • ||||||||||  Lipax (proliposomal intravesical paclitaxel) / TesoRx
    Enrollment closed, Trial completion date, Trial primary completion date:  Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (clinicaltrials.gov) -  Sep 2, 2020   
    P1/2,  N=15, Active, not recruiting, 
    Persistence of paclitaxel in the voided urine at therapeutic concentrations up to 72 hours after instillation were observed. Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: May 2020 --> Aug 2020
  • ||||||||||  proliposomal intravesical paclitaxel (TSD-001) / TesoRx
    [VIRTUAL] PHASE 1 OUTCOMES OF A NOVEL THIRD GENERATION LIPOSOMAL PACLITAXEL FORMULATION (TSD-001) IN LOW-INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS (WEWCC: 147B) -  May 17, 2020 - Abstract #AUA2020AUA_2483;    
    NMIBC patients exposed to escalating TSD-001 dose (10-540 mg paclitaxel) until maximum deliverable dose (540 mg) demonstrated no DLT.  Voiding function and bother were unchanged from baseline to completion.  There was no evidence of systemic paclitaxel exposure based on a valid bioanalytical assess.  No evidence of TCCa recurrence  has been observed at a mean follow-up of 12 months.  TSD-001 delivers high urinary concentrations of paclitaxel with no measurable systemic exposure, and is very well tolerated in NMIBC patients. Source of Funding: Lipac Oncology, LLC
  • ||||||||||  Lipax (proliposomal intravesical paclitaxel) / TesoRx
    Enrollment open, Trial completion date, Trial primary completion date:  Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (clinicaltrials.gov) -  Apr 19, 2018   
    P1/2,  N=16, Enrolling by invitation, 
    Enrolling by invitation --> Recruiting Not yet recruiting --> Enrolling by invitation | Trial completion date: Sep 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Jun 2019
  • ||||||||||  Lipax (proliposomal intravesical paclitaxel) / TesoRx
    Trial initiation date, Trial primary completion date:  Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (clinicaltrials.gov) -  Oct 12, 2017   
    P1/2,  N=16, Not yet recruiting, 
    Not yet recruiting --> Enrolling by invitation | Trial completion date: Sep 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Jun 2019 Initiation date: Jun 2017 --> Dec 2017 | Trial primary completion date: Feb 2018 --> Aug 2018